Mikrobiomik develops biological medications derived from human gut microbiota to treat severe infections, such as Clostridioides difficile, where effective therapeutic alternatives are lacking. The company is pioneering clinical trials for additional indications, including metabolic dysfunction and colorectal cancer, to expand treatment options based on microbiome research.
Funding
$9.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe infections, such as Clostridioides difficile, lack effective therapeutic alternatives, leading to high morbidity and mortality rates. Current treatments often fail to address the underlying microbiome imbalances that contribute to recurrent infections and other complications. Furthermore, metabolic dysfunction associated with steatohepatitis (MASH), acute uncomplicated diverticulitis, and metastatic colorectal cancer also present significant therapeutic challenges.
Solution
Mikrobiomik is a biopharmaceutical company developing a new generation of biological drugs based on the human gut microbiome to address severe diseases. Their lead candidate, MBK-01, is designed to treat Clostridioides difficile infections, including both primary episodes and recurrences, by restoring a healthy gut microbiota. The company has completed a Phase III clinical trial for ICD-01 and is preparing to commercialize the first microbiome-based biological drug in the EU. Mikrobiomik is also conducting clinical trials for additional indications, including metabolic dysfunction-associated steatohepatitis (MASH), acute uncomplicated diverticulitis, and a proof-of-concept study for metastatic colorectal cancer.
Target Audience
The primary target audience includes patients suffering from severe infections like Clostridioides difficile, individuals with metabolic dysfunction associated with steatohepatitis (MASH), and those affected by acute uncomplicated diverticulitis and metastatic colorectal cancer, as well as the healthcare professionals who treat them.
Features
- MBK-01: A biological drug based on the intestinal microbiota for treating Clostridioides difficile infections.
- ICD-01: Phase III clinical trial completed for the treatment of Clostridioides difficile infections.
- Pipeline includes treatments for metabolic dysfunction-associated steatohepatitis (MASH).
- Investigational therapies for acute uncomplicated diverticulitis.
- Proof-of-concept study for the treatment of metastatic colorectal cancer.
- Focus on restoring a healthy gut microbiota to address the root cause of disease.
- Development of biological drugs based on the human microbiome.